eFFECTOR Therapeutics IncOver The Counter Market:EFTR
- LAST PRICE0.0002
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0002 / 0.0002
- Day Range
- 52 Week Range
- Volume1,282
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | EFTR |
|---|---|---|
| 12:35 ET | 100 | 0.0002 |
| 12:37 ET | 300 | 0.0002 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
eFFECTOR Therapeutics Inc | 940.0 | 0.0x | --- |
GeneThera Inc | 3.5K | 0.0x | --- |
Verde Science Inc | 20.0 | 0.0x | --- |
HempAmericana Inc | 2.9K | --- | --- |
Adhera Therapeutics Inc | 17.3K | 0.0x | --- |
Netmed Inc | 10.0 | 0.0x | --- |
Company Information
eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology drugs, such as selective translation regulator inhibitors (STRIs). The Company uses a selective translation regulation technology platform to internally discover a portfolio of small molecule STRI product candidates. Its product candidates target the eIF4F complex and its activating kinase, MNK. The Company’s lead product candidate, tomivosertib, is an inhibitor of MNK, and is being evaluated in combination with KEYTRUDA (pembrolizumab), an FDA-approved inhibitor of programmed cell death protein 1 (PD-1) in a randomized Phase 2b clinical trial in patients with metastatic non-small cell lung cancer (NSCLC). Its second product candidate, zotatifin, is an inhibitor of eIF4A, a component of the eIF4F complex, and is being evaluated in a Phase 1/2 clinical trial in patients with certain solid tumors. Its third program is focused on developing inhibitors of eIF4E.
Contact Information
- Headquarters
- 142 North Cedros Avenue Suite B, Suite ASOLANA BEACH, CA, United States 92075
- Phone
- 858-925-8215
- Fax
- 302-655-5049
Executives
- President, Chief Executive Officer, Treasurer, Company Secretary, Director
- Craig Jalbert
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $940.00 |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 4.7M |
eFFECTOR Therapeutics Inc does not pay a dividend. | |
Beta | 0.67 |
EPS | $-13.31 |
Book Value | $-1.94 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
